Fig. 1From: Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meetingProposed treatment sequencing for the management of HR + HER2 − mBCBack to article page